Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report’s forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.

The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the biggest application segment of the CMV therapeutics market that year.

The global HPV and CMV therapeutics market is segmented into five major regions: North America, South America, Europe, Asia Pacific, and Rest of the World. North America led the global HPV and CMV therapeutics market in 2013 in term of revenue. The HPV market in the region is driven by a rise in the sexually active population, increase in diagnostic rate, and growing international migration. The CMV therapeutics market in North America is fueled by increasing cost of drugs, rise in organ transplant surgeries, and high risk of STDs. The South America and Asia Pacific region are both estimated to witness significant growth in the HPV and CMV therapeutics market by 2020.

Browse the full Human Papillomavirus Report at http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html


Clinigen Group plc, Perrigo Company plc, Roche Holdings AG, Merck & Co., Inc., AbbVie, Inc., Actavis plc, and Valeant Pharmaceuticals International, Inc. are the companies profiled in the HPV and CMV therapeutics market report. The CMV therapeutics market was dominated by Roche AG in 2013, thanks to Valcyte being the sole branded formulation available in the market. The HPV therapeutics market was led by Valeant Pharmaceuticals in 2013, owing to the success of its leading brands Aldara, Zyclara, Efudex, and Carac.Each of the players featured in this report are profiled based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies such as mergers and acquisitions, geographic expansions, R&D practices, collaborations and agreements, and product launches.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=3986

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com